Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 244

Similar articles for PubMed (Select 10874050)

1.

Impact of genomics on drug discovery and clinical medicine.

Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM.

QJM. 2000 Jul;93(7):391-423. Review.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

The era of genomics: impact on sepsis clinical trial design.

Cariou A, Chiche JD, Charpentier J, Dhainaut JF, Mira JP.

Crit Care Med. 2002 May;30(5 Suppl):S341-8. Review.

PMID:
12004257
4.

Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.

Terra SG, Johnson JA.

Am J Cardiovasc Drugs. 2002;2(5):287-96. Review.

PMID:
14727958
5.

Human genome project: pharmacogenomics and drug development.

Ganguly NK, Bano R, Seth SD.

Indian J Exp Biol. 2001 Oct;39(10):955-61. Review.

PMID:
11883519
6.

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW.

Pharmacogenomics J. 2007 Feb;7(1):10-28. Epub 2006 Jun 13. Review.

PMID:
16770341
7.

Molecular genetics of Alzheimer's disease and aging.

Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M.

Methods Find Exp Clin Pharmacol. 2005 Jul;27 Suppl A:1-573.

PMID:
16470248
8.

Functional genomics and proteomics--the role of nuclear medicine.

Haberkorn U, Altmann A, Eisenhut M.

Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):115-32. Epub 2001 Nov 14. Review.

PMID:
11807614
9.

Pharmacogenomics of neurodegenerative diseases.

Maimone D, Dominici R, Grimaldi LM.

Eur J Pharmacol. 2001 Feb 9;413(1):11-29. Review.

PMID:
11173059
10.

Integrating genomics across drug discovery and development.

Debouck C.

Toxicol Lett. 2009 Apr 10;186(1):9-12. doi: 10.1016/j.toxlet.2008.09.011. Epub 2008 Sep 26.

PMID:
18930125
11.

Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.

Ganesh SK, Skelding KA, Mehta L, O'Neill K, Joo J, Zheng G, Goldstein J, Simari R, Billings E, Geller NL, Holmes D, O'Neill WW, Nabel EG.

Pharmacogenomics. 2004 Oct;5(7):952-1004.

PMID:
15469413
12.
13.

Pharmacogenomics: challenges and opportunities.

Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST; Pharmacogenetics Research Network.

Ann Intern Med. 2006 Nov 21;145(10):749-57. Review.

PMID:
17116919
14.

[Pharmacogenomics genomics approaches to optimizing drug therapy].

Shi J, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Apr;19(2):156-8. Review. Chinese.

PMID:
11941596
15.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
16.

The genomics revolution and radiotherapy.

West CM, Elliott RM, Burnet NG.

Clin Oncol (R Coll Radiol). 2007 Aug;19(6):470-80. Epub 2007 Apr 6. Review.

PMID:
17419040
17.

Genomics in drug discovery: the best things come to those who wait.

Bansal AT, Barnes MR.

Curr Opin Drug Discov Devel. 2008 May;11(3):303-11. Review.

PMID:
18428083
18.

Fruits of human genome project and private venture, and their impact on life science.

Ikekawa A, Ikekawa S.

Yakugaku Zasshi. 2001 Dec;121(12):845-73. Review.

19.

Pharmacogenetics approach to therapeutics.

Koo SH, Lee EJ.

Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):525-32. Review.

PMID:
16700889
20.

A genomic "roadmap" to "better" drugs.

Liao G, Zhang X, Clark DJ, Peltz G.

Drug Metab Rev. 2008;40(2):225-39. doi: 10.1080/03602530801952815 . Review.

PMID:
18464044
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk